Corbion Q3 2021 Interim Management Statement
Corbion reported net sales of € 797.6 million in the first nine months of 2021, driven by organic net sales growth of 15.7%. Adjusted EBITDA in the first nine months of 2021 decreased organically by 2.4% to € 113.5 million.
“The third quarter showed a continuation of the strong sales growth in the previous quarters. Sustainable Food Solutions is showing organic growth due to our higher win-rates in Functional Systems, while in Preservation, our natural solutions continue to win share in the overall preservation market. The very positive development in the PLA JV has been a key driver in Lactic Acid & Specialties growth. In Incubator we see positive momentum as growth in Q3 continued at a brisk pace as algae-based omega-3 is seeing increased market receptiveness in the aquaculture market.
As we indicated at the first half results, one of the key priorities is to restore our core margin. Input cost inflation is impacting our profitability, as there is a time lag of our sales pricing catching up with the higher input prices. Sales price increases have already been achieved for a number of contracts. In addition to these price increases, we will be benefit from higher volumes, and we will continue to drive operational efficiencies.
We are encouraged by the continued strong sales pipeline and sales growth momentum. The Advance 2025 strategy, intended to boost growth, is clearly materializing”, commented Olivier Rigaud, CEO.
Key financial highlights first nine months of 2021
- Net sales growth YTD was 7.6%; organic growth was 15.7% (16.3% for core activities)
- Adjusted EBITDA YTD was € 113.5 million, an organic decrease of 2.4%
- Adjusted EBITDA margin YTD was 14.2% (14.1% for core activities)
- Operating result YTD was € 95.5 million, an organic increase of 16.8%
€ million | YTD 2021 | YTD 2020 | Total growth | Organic growth |
Net sales | 797.6 | 741.2 | 7.6% | 15.7% |
Adjusted EBITDA | 113.5 | 128.4 | -11.6% | -2.4% |
Adjusted EBITDA margin | 14.2% | 17.3% | ||
Operating result | 95.5 | 89.4 | 6.8% | 16.8% |
Attachment
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HireRight, and Doximity Innovations and Encourages Investors to Contact the Firm
- ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation – LFCR, LNDC
- YPF SA reports
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Raising PricesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!